98 related articles for article (PubMed ID: 1864985)
1. Globin chain synthesis in myelodysplastic syndromes.
Chalevelakis G; Karaoulis S; Yalouris AG; Economopoulos T; Tountas N; Raptis S
J Clin Pathol; 1991 Feb; 44(2):134-8. PubMed ID: 1864985
[TBL] [Abstract][Full Text] [Related]
2. Effect of isoniazid, a haem inhibitor, on globin chain synthesis in reticulocytes from non-thalassaemic and beta thalassaemic subjects.
Chalevelakis G; Yalouris AG; Lyberatos C; Economopoulos T; Anastasiou C; Hatziioannou J; Raptis S
J Clin Pathol; 1989 Sep; 42(9):977-81. PubMed ID: 2794087
[TBL] [Abstract][Full Text] [Related]
3. Increased alpha:non-alpha globin chain synthesis ratios in myelodysplastic syndromes and myeloid leukaemia.
Peters RE; May A; Jacobs A
J Clin Pathol; 1986 Nov; 39(11):1233-5. PubMed ID: 3466903
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
[TBL] [Abstract][Full Text] [Related]
5. Globin chain synthesis ratios in sideroblastic anaemia.
Peters RE; May A; Jacobs A
Br J Haematol; 1983 Feb; 53(2):201-9. PubMed ID: 6821649
[TBL] [Abstract][Full Text] [Related]
6. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of c-myc p67 oncoprotein in patients with myelodysplastic syndromes in transformation to acute leukaemia.
Kyriakou D; Eliopoulos AG; Alexandrakis M; Kalokyri I; Eliopoulos GD
Haematologia (Budap); 1996; 28(1):1-7. PubMed ID: 9283897
[TBL] [Abstract][Full Text] [Related]
8. Interaction between iron deficiency and alpha-thalassaemia: the in vitro effect of haemin on alpha-chain synthesis.
el-Hazmi MA; Lehmann H
Acta Haematol; 1978; 60(1):1-9. PubMed ID: 97895
[TBL] [Abstract][Full Text] [Related]
9. [Chromosome abnormalities in myelodysplastic syndrome].
Fujita K; Mori H; Niikura H; Terada H; Shinohara T
Rinsho Byori; 1990 Aug; 38(8):911-6. PubMed ID: 2232253
[TBL] [Abstract][Full Text] [Related]
10. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome.
Dalamaga M; Karmaniolas K; Chamberland J; Nikolaidou A; Lekka A; Dionyssiou-Asteriou A; Mantzoros CS
Metabolism; 2013 Dec; 62(12):1830-9. PubMed ID: 24140093
[TBL] [Abstract][Full Text] [Related]
11. [Retrospective analysis of hemotherapy support in 226 cases of myelodysplastic syndromes].
Rubio-Félix D; Franco E; Giraldo P; Gimeno J; Cuesta I; Giralt M
Sangre (Barc); 1994 Apr; 39(2):117-20. PubMed ID: 8059289
[TBL] [Abstract][Full Text] [Related]
12. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
13. [Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].
Dewulf G; Gouin I; Pautas E; Gaussem P; Chaïbi P; Andreux JP; Siguret V
Ann Biol Clin (Paris); 2004; 62(2):197-202. PubMed ID: 15047472
[TBL] [Abstract][Full Text] [Related]
14. [Prediction of survival in myelodysplastic syndrome. Analysis of 2 scoring systems with prognostic value].
Sanz GF; Sanz MA; Vallespí T; Cañizo MC; García S; Torrabadella M; San Miguel JF; Irriguible D
Sangre (Barc); 1989 Feb; 34(1):41-6. PubMed ID: 2711284
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes.
Alexandrakis M; Coulocheri S; Xylouri I; Ganotakis E; Eliakis P; Karkavitsas N; Eliopoulos GD
Haematologia (Budap); 1998; 29(1):13-24. PubMed ID: 9704253
[TBL] [Abstract][Full Text] [Related]
16. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
17. Primary myelodysplastic syndrome: clinical spectrum of 53 cases.
Irfan M; Kakepoto GN; Khursheed M
J Pak Med Assoc; 1998 Mar; 48(3):69-73. PubMed ID: 9783031
[TBL] [Abstract][Full Text] [Related]
18. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
[TBL] [Abstract][Full Text] [Related]
19. [Culture of cells forming granulomonocytic colonies in bone marrow (GM-CFU) in myelodysplastic syndromes and their relation to hematological findings and FAB subtype].
García M; Sanz GF; Arriaga F; Pérez-Sirvent ML; Marty ML; Sanz MA
Sangre (Barc); 1991 Aug; 36(4):269-75. PubMed ID: 1776105
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic syndromes (MDS) in Zimbabweans--preliminary observations.
Mukiibi JM; Paul B
East Afr Med J; 1989 Mar; 66(3):155-61. PubMed ID: 2591323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
